文献速递免疫规划传染病防控与疫情报告

HIV感染者接种乙型肝炎疫苗后的长期保护效果

Long-term protection after hepatitis B vaccination in people living with HIV.
PubMed 文献 · Vaccine · 2017-06-29

该回顾性研究分析了巴西圣保罗121例HIV感染者2001至2002年初次接种乙型肝炎疫苗后的长期免疫持久性。11年后无人出现HBV感染血清学证据,初次应答者中70.7%维持anti-HBs≥10mIU/mL;初次无应答者经加强针后55.6%成功血清学转换,未再加强者10年后77.1%维持anti-HBs≥10mIU/mL。

要点

  • 11年后无人出现HBV感染血清学证据。
  • 初次应答者70.7%维持anti-HBs≥10mIU/mL。
  • 初次无应答者加强针后55.6%血清学转换。

核心结论

  • HIV感染者接种乙型肝炎疫苗后长期随访显示anti-HBs持久性较强且无HBV感染血清学证据,加强针可能对初次无应答者有效。

研究设计与样本

  • 回顾性研究,纳入2001至2002年初次接种乙型肝炎疫苗的HIV感染者队列,2012至2014年在巴西圣保罗门诊随访,分析121例。

主要发现

  • 11年后无人出现HBV感染血清学证据。
  • 初次应答者(第1组)41/58(70.7%)维持anti-HBs≥10mIU/mL。
  • 初次无应答者(第2组)35/63(55.6%)经一次或多次加强针后成功血清学转换(anti-HBs≥10mIU/mL)。
  • 血清学转换后未再加强者(第3组)10年后54/70(77.1%)维持anti-HBs≥10mIU/mL。
  • 首次疫苗系列时较高的CD4+值和anti-HBs>100mIU/mL与anti-HBs持久性相关。

临床怎么用

  • 作者认为加强针可能对HIV感染者初次接种无应答者有效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatitis B vaccine is important in people living with HIV (PLHIV) since both viruses have the same transmission routes and co-infection has greater morbidity. PLHIV usually have poor response to hepatitis B vaccine. The duration of immunity in PLHIV is unknown. The objective of this study is to evaluate the duration of serological response and clinical protection provided by hepatitis B vaccination in PLHIV. METHODS: Retrospective study of a PLHIV cohort primarily vaccinated for hepatitis B virus (HBV) from 2001 to 2002. Markers of infection and protection from HBV were investigated in those individuals who were still attending the outpatient clinic, in São Paulo, Brazil from 2012 to 2014. Three groups were analyzed. Group 1: adults who responded to primary vaccine series. Group 2: non-responders to primary vaccine series. Group 3: subjects from both Groups 1 and 2 who did not receive any booster doses after seroconversion. RESULTS: A cohort of 121 PLHIV was analyzed for seroconversion and persistence of anti-HBs. The majority were female (54.5%) and mean age was 50.1years. After 11years, none of the patients had serologic evidence of HBV infection. Overall, 41/58 (70.7%) of the initial responders (Group 1) had maintained anti-HBs≥10mIU/mL. Greater CD4+ values and anti-HBs>100mIU/mL at the time of first vaccine series were associated with persistence of anti-HBs. During the time of evaluation, 35/63 (55.6%) of the initial non-responders (Group 2) successfully seroconverted (anti-HBs≥10mIU/mL) in response to one or more booster doses. From the time of their seroconversion, 70 of the patients did not receive any further booster doses (Group 3). After 10years, 54/70 (77.1%) of these individuals has maintained anti-HBs≥10mIU/mL. CONCLUSIONS: Evaluation of long-term immunity for hepatitis B in PLHIV following vaccination showed a strong persistence of anti-HBs and no serologic evidence of HBV infection. Boosters may be effective in PLHIV non-responders to primary vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lara AN, Sartori AM, Fonseca MO, et al. Long-term protection after hepatitis B vaccination in people living with HIV. Vaccine. 2017. PMID: 28669615. doi:10.1016/j.vaccine.2017.06.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。